These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36671290)

  • 1. A Post Hoc Analysis of Efficacy Data on Sarecycline in Hispanics with Acne from Two Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trials.
    Moore AY; Hurley K; Moore SA
    Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials.
    Moore A; Green LJ; Bruce S; Sadick N; Tschen E; Werschler P; Cook-Bolden FE; Dhawan SS; Forsha D; Gold MH; Guenthner S; Kempers SE; Kircik LH; Parish JL; Rendon MI; Rich P; Stein-Gold L; Tyring SK; Weiss RA; Nasir A; Schmitz C; Boodhoo TI; Kaoukhov A; Berk DR
    J Drugs Dermatol; 2018 Sep; 17(9):987-996. PubMed ID: 30235387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Sarecycline, a Novel, Once-Daily, Narrow Spectrum Antibiotic for the Treatment of Moderate to Severe Facial Acne Vulgaris: Results of a Phase 2, Dose-Ranging Study.
    Leyden JJ; Sniukiene V; Berk DR; Kaoukhov A
    J Drugs Dermatol; 2018 Mar; 17(3):333-338. PubMed ID: 29537451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sarecycline Review.
    Haidari W; Bruinsma R; Cardenas-de la Garza JA; Feldman SR
    Ann Pharmacother; 2020 Feb; 54(2):164-170. PubMed ID: 31462063
    [No Abstract]   [Full Text] [Related]  

  • 5. Management of Truncal Acne With Oral Sarecycline: Pooled Results from Two Phase-3 Clinical Trials.
    Del Rosso JQ; Stein Gold L; Baldwin H; Harper JC; Zeichner J; Obagi S; Graber E; Jimenez X; Vicente FH; Grada A
    J Drugs Dermatol; 2021 Jun; 20(6):634-640. PubMed ID: 34076386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris: Results from a Phase III, Multicenter, Open-Label Study and a Phase I Phototoxicity Study.
    Pariser DM; Green LJ; Lain EL; Schmitz C; Chinigo AS; McNamee B; Berk DR
    J Clin Aesthet Dermatol; 2019 Nov; 12(11):E53-E62. PubMed ID: 32038757
    [No Abstract]   [Full Text] [Related]  

  • 7. Sarecycline: a narrow spectrum tetracycline for the treatment of moderate-to-severe acne vulgaris.
    Moore AY; Charles JEM; Moore S
    Future Microbiol; 2019 Sep; 14(14):1235-1242. PubMed ID: 31475868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral Sarecycline for Treatment of Papulopustular Rosacea: Results of a Pilot Study of Effectiveness and Safety.
    Rosso JQ; Draelos ZD; Effron C; Kircik LH
    J Drugs Dermatol; 2021 Apr; 20(4):426-431. PubMed ID: 33852248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of sarecycline for the treatment of moderate-to-severe acne vulgaris.
    Valente Duarte de Sousa IC
    Expert Opin Pharmacother; 2021 Feb; 22(2):145-154. PubMed ID: 32924666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sarecycline hydrochloride for the treatment of acne vulgaris.
    Kaul G; Saxena D; Dasgupta A; Chopra S
    Drugs Today (Barc); 2019 Oct; 55(10):615-625. PubMed ID: 31720559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sarecycline treatment for acne vulgaris: Rationale for weight-based dosing and limited impact of food intake on clinical efficacy.
    Grada A; Del Rosso JQ; Graber E; Bunick CG; Stein Gold L; Moore AY; Baldwin H; Obagi Z; Damiani G; Carrothers T; McNamee B; Hanze E
    Dermatol Ther; 2022 Mar; 35(3):e15275. PubMed ID: 34923732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic Resistance Risk with Oral Tetracycline Treatment of Acne Vulgaris.
    Swallow MA; Fan R; Cohen JM; Bunick CG
    Antibiotics (Basel); 2022 Jul; 11(8):. PubMed ID: 36009899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarecycline: A Review of Preclinical and Clinical Evidence.
    Moore AY; Del Rosso J; Johnson JL; Grada A
    Clin Cosmet Investig Dermatol; 2020; 13():553-560. PubMed ID: 32884318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sarecycline: A Narrow-Spectrum Antibiotic.
    Adjei S; Miller AC; Temiz LA; Tyring SK
    Skin Therapy Lett; 2022 May; 27(3):5-7. PubMed ID: 35533371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris.
    Zhanel G; Critchley I; Lin LY; Alvandi N
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Sarecycline on the Acne Symptom and Impact Scale and Concerns in Moderate-to-Severe Truncal Acne in Open-Label Pilot Study.
    Moore AY; Hurley K; Moore SA; Moore L; Zago I
    Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARECYCLINE AND THE NARROW-SPECTRUM TETRACYCLINE CONCEPT: Currently Available Data and Potential Clinical Relevance in Dermatology.
    Del Rosso JQ
    J Clin Aesthet Dermatol; 2020 Oct; 13(10):45-48. PubMed ID: 33584958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiling the Effects of Systemic Antibiotics for Acne, Including the Narrow-Spectrum Antibiotic Sarecycline, on the Human Gut Microbiota.
    Moura IB; Grada A; Spittal W; Clark E; Ewin D; Altringham J; Fumero E; Wilcox MH; Buckley AM
    Front Microbiol; 2022; 13():901911. PubMed ID: 35711781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris.
    Lucky AW; Henderson TA; Olson WH; Robisch DM; Lebwohl M; Swinyer LJ
    J Am Acad Dermatol; 1997 Nov; 37(5 Pt 1):746-54. PubMed ID: 9366821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation.
    Bunick CG; Keri J; Tanaka SK; Furey N; Damiani G; Johnson JL; Grada A
    Antibiotics (Basel); 2021 Apr; 10(4):. PubMed ID: 33920812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.